Biliary Tract Cancer Market Growth
Over the past few years, the Biliary Tract Cancer (BTC) has claimed many lives worldwide. Biliary Tract Cancer is an epithelial malignancy of the biliary tree. It is observed that nearly 3% of all gastrointestinal malignancies are established by BTC, and after hepatocellular carcinoma, it is one of the most common hepatobiliary cancers.
In the coming years, owing to vast unmet needs, especially for the treatment for the Biliary Tract Cancer patients and the onset of technological advancements and research and development, the Biliary tract cancer market is expected to evolve significantly.
Worldwide, some of the key Biliary Tract Cancer companies are developing therapies for the condition, Ivosidenib Agios Pharmaceuticals, QED Therapeutics, Delcath Systems, Taiho Oncology, Merck Sharp & Dohme, Delcath Systems, AstraZeneca, Ipsen, BeiGene, Merck Sharp & Dohme, Celgene, PCI Biotech, Eisai, Bristol-Myers Squibb, Bayer, Basilea Pharmaceutica and others that are expected to enter the market by 2030, which will fuel the growth of the Biliary tract cancer market size.